Navigation Links
Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
Date:8/29/2008

SEATTLE, Aug. 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Greg Schiffman, chief financial officer of Dendreon, will present a company update at the Newsmakers in the Biotech Industry Conference in New York City, on Thursday, September 4, 2008 at 3:55 p.m. ET.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Dendreon website, http://www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Reports First Quarter 2008 Financial Results
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Announces Closing of Registered Direct Offering
5. Dendreon Announces $47 Million Registered Direct Offering
6. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
7. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
8. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
9. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
10. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
11. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 FamilyFarms Group ... General Manager of State Line Farms, received the 2015 ... a producer, under the age of 35, who has ... is an honor to win the Tomorrow's Top Producer ... who won the Top Producer Award and learning from ...
(Date:2/27/2015)... , Feb. 27, 2015  Steep Hill, the industry ... and internationally, intends to open a full service medical ... Mexico , bringing advanced scientific tools and methodology ... Steep Hill is currently the only laboratory licensed ... potency and contaminant testing in order to meet the ...
(Date:2/26/2015)... Feb. 26, 2015 S&P Capital IQ (MHFI) ... Report coverage on MabVax Therapeutics Holdings Inc . ... clinical stage biotechnology company focused on the development of ... in the treatment of cancer. MabVax has discovered a ... protective immune responses generated by patients who have been ...
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015 /PRNewswire/ ... appointment of Kate Black as Privacy Officer ... international, federal, and state privacy laws as well as ... and regulatory team, she will be responsible for reviewing, ... for customers in the U.S. and abroad. She joined ...
Breaking Biology Technology:Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... ARLINGTON, Va., July 13 The Generic Pharmaceutical Association ... Kathleen Jaeger on the Senate HELP Committee,s vote on biogenerics legislation. ... disappointed that the Committee action could result in patients having little ... in the House to ensure that a true balance is achieved ...
... 13, 2009) Whitehead Institute scientists have developed a ... target diseases that until now have stymied drug developers, ... yeast to synthesize and screen the molecules, cutting target ... weeks. The current drug discovery process ...
... ERT (Nasdaq: ERES ), a leading provider of ... medical device, and related industries, announced today that it will release ... 2009 after the market closes. After the release, the Company will ... , For the conference call, interested ...
Cached Biology Technology:GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients 2New method may accelerate drug discovery for difficult diseases like Parkinson's 2New method may accelerate drug discovery for difficult diseases like Parkinson's 3New method may accelerate drug discovery for difficult diseases like Parkinson's 4ERT to Announce 2009 Second Quarter Results on July 30, 2009 2
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... AURORA, Colo. (Dec. 9, 2013) A new study shows ... concussions than those closer to sea-level, a phenomenon attributed to ... tightly in the skull. "This is the first time ... Comstock, PhD, associate professor of epidemiology at the Colorado School ...
... Liver (EASL) today publishes their revised Clinical Practice Guidelines ... (HCV) (1). The EASL guidelines, which supersede the ... physicians and other healthcare providers optimise their management of ... estimated that approximately 160 million individuals, i.e. 2.35% of ...
... of tumours in over one per cent of all cancer ... has been broadly linked to cancer development. The team ... activated that increases tumour growth. Drugs that inhibit the biological ... in development thus highlighting a potential new targeted therapy for ...
Cached Biology News:Study shows first link between altitude and concussion 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 3Gene promotes 1 in 100 of tumors 2
... glycerol stocks contained in standard 96-well microtiter ... with approximately 5,000 clones per plate. After ... well, the corresponding subplate is screened with ... positive well(s). Cells from a positive well ...
... designed for flexibility and routine operation. With ... lens, true hyperbolic quadrupole and high-speed simultaneous ... range of sample types and applications. New ... standard Agilents unique ShieldTorch System, which enables ...
... is a fully automated microplate luminescence ... widest possible range of applications based ... assays luciferase, -galactosidase, gene activities with ... Luminescent Immunoassays Cell-based assays ...
... depleted sera are specifically depleted of a ... the depleted protein, the alternative and classical ... therefore ideal for the detection and quantitation ... have been used to assess complement activation ...
Biology Products: